tbuckley/cabot-search huggingface dataset:
Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup
Authors: V. D’Hondt, J.-L. Canon, L. ROCA, C. Levy, J.-Y. Pierga, F Le Du, M. Campone, I. Desmoulins, P. Viens, M. Debled, J.-M. Ferrero, D. Serin, A -C Hardy Bessard, E. Brain, N. Dohollou, H. Orfeuvre, J. Lemonnier, H. Roche, S. Delaloge, F. Dalenc
Journal: Annals of Oncology (2019)
SP0014 The differential diagnosis of diffuse sclerosing skin disease and a practical approach to assessment
Authors: J Pauling
Journal: Annals of the Rheumatic Diseases (2017)

The differential diagnosis for sclerosing skin disease is broad but there are clinical and laboratory features that can help guide clinicians to the correct diagnosis. This presentation shall provide a comprehensive review of the spectrum of sclerosing skin disease. A practical approach to interpreting the clinical, serological, microvascular imaging and histological features that can help differentiate disease states shall be presented to provide rheumatologists with a practical approach to the assessment of patients with sclerosing skin disease. Case histories shall be used to illustrate the pertinent clinical features and investigative approaches that can help distinguish systemic sclerosis from other sclerosing skin conditions such as scleroedema, pan-sclerotic morphoea, lipodermatosclerosis and chronic graft versus host disease. A specific focus shall be placed on the role of autoantibodies in the diagnosis of systemic sclerosis, including recent work reporting the presence of novel systemic sclerosis-specific autoantibodies in patients with antinuclear antibody-negative diffuse cutaneous systemic sclerosis. <h3>Disclosure of Interest</h3> J. Pauling Grant/research support from: Actelion pharmaceuticals, Consultant for: Actelion pharmaceuticals, Speakers bureau: Actelion pharmaceuticals
Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting
Authors: F. Roghmann, R. Wirtz, J. Jarczyk, M.C. Kriegmair, T.S. Worst, D. Sikic, S. Wach, H. Taubert, B. Wullich, V. Weyerer, R. Stoehr, F. Zengerling, C. Bolenz, J. Breyer, M. Burger, S. Porubsky, A. Hartmann, P. Erben, M. Eckstein, H. Juette
Journal: Annals of Oncology (2019)
Reduction in Mental Health Treatment Utilization Among Transgender Individuals After Gender-Affirming Surgeries: A Total Population Study
Authors: Richard Bränström, John E. Pachankis
Journal: American Journal of Psychiatry (2019)

Objective: Despite professional recommendations to consider gender-affirming hormone and surgical interventions for transgender individuals experiencing gender incongruence, the long-term effect of such interventions on mental health is largely unknown. The aim of this study was to ascertain the prevalence of mood and anxiety disorder health care visits and antidepressant and anxiolytic prescriptions in 2015 as a function of gender incongruence diagnosis and gender-affirming hormone and surgical treatment in the entire Swedish population. Methods: This study used the Swedish Total Population Register (N=9,747,324), linked to the National Patient Register and the Prescribed Drug Register. Among individuals who received a diagnosis of gender incongruence (i.e., transsexualism or gender identity disorder) between 2005 and 2015 (N=2,679), mental health treatment in 2015 was examined as a function of length of time since gender-affirming hormone and surgical treatment. Outcome measures were mood and anxiety disorder health care visits, antidepressant and anxiolytic prescriptions, and hospitalization after a suicide attempt. Results: Compared with the general population, individuals with a gender incongruence diagnosis were about six times as likely to have had a mood and anxiety disorder health care visit, more than three times as likely to have received prescriptions for antidepressants and anxiolytics, and more than six times as likely to have been hospitalized after a suicide attempt. Years since initiating hormone treatment was not significantly related to likelihood of mental health treatment (adjusted odds ratio=1.01, 95% CI=0.98, 1.03). However, increased time since last gender-affirming surgery was associated with reduced mental health treatment (adjusted odds ratio=0.92, 95% CI=0.87, 0.98). Conclusions: In this first total population study of transgender individuals with a gender incongruence diagnosis, the longitudinal association between gender-affirming surgery and reduced likelihood of mental health treatment lends support to the decision to provide gender-affirming surgeries to transgender individuals who seek them.
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Authors: H. Tesch, S. Loibl, K. Kast, C. Jackisch, V. Möbus, S. Buchen, M. Untch, C. Hanusch, S. Seiler, M. Weigel, P.A. Fasching, K. Rhiem, J. Huober, J.-U. Blohmer, C. Solbach, C. Denkert, V. Nekljudova, T. Link, A. Schneeweiss
Journal: Annals of Oncology (2019)
METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
Authors: L.L. Siu, D.W. Rasco, S Postel Vinay, P Martin Romano, J. Menis, F.L. Opdam, K.M. Heinhuis, J.L. Egger, S.A. Gorman, R. Parasrampuria, K. Wang, B.E. Kremer, M.M. Gounder
Journal: Annals of Oncology (2019)
Abstract 13003: Mechanism of Aneurysm Expansion After Endovascular Aortic Repair Analyzed With X-Ray Phase-Contrast Tomography
Authors: Takateru Yamamoto, Kenji Okada, Naoki Yagi, Masato Hoshino, Yutaka Nakashima, Kazunori Nakagawa, Takuro Tsukube
Journal: Circulation (2018)

Objectives: Synchrotron radiation-based X-ray phase-contrast tomography (XPCT) has proven innovative modality for analyzing 3D morphology and is useful for understanding the pathophysiology of vari...
Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Authors: F.G.M. De Braud, S. Siena, F. Barlesi, A. Drilon, B.P. Simmons, X. Huang, C. Ye, R.C. Doebele
Journal: Annals of Oncology (2019)
Live Offspring after Testis Tissue Transplantation
Authors: Takehiko Ogawa
Journal: New England Journal of Medicine (2019)

Subcutaneous allogeneic grafts derived from cells cultured from the cryopreserved testis tissue of prepubertal rhesus monkeys can differentiate and produce spermatids and spermatozoa, a finding with implications for the reproductive potential of prepubertal boys rendered sterile by medical treatment.
The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC): Pooled analysis of 6 clinical trials
Authors: E. Fountzilas, G.-A. Koliou, F. Zagouri, G. Pentheroudakis, C. Christodoulou, A. Koutras, D.G. Pectasides, D. Bafaloukos, E. Samantas, G. Aravantinos, P. Papakostas, A. Psyrri, P.A. Kosmidis, A. Koumarianou, E. Razis, H. Linardou, A. Christopoulou, C. Karanikiotis, H. Gogas, G. Fountzilas
Journal: Annals of Oncology (2019)
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Authors: M.L. Friedlander, K. Moore, N. Colombo, G. Scambia, B.-G. Kim, A. Oaknin, A. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, S. Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, E. Lowe, R. Hettle, E. Flood, P. DiSilvestro
Journal: Annals of Oncology (2019)
Prognostic significance of progesterone receptor levels in luminal-like Her2- early breast cancer patients. A retrospective single cancer center analysis
Authors: A. Diana, F. Carlino, E. Franzese, S. Centonze, L.P. Guerrera, A. Perrone, F. De Vita, F. Ciardiello, M. Orditura
Journal: Annals of Oncology (2019)
Repopulation of Lymphocytes and Natural Killer Cells on Day 15 Following First Autologous Stem Cell Transplantation in Myeloma Patients Correlates with the Number of Reinfused Lymphocytes and Natural Killer T Cells in the Autologous Graft
Authors: Matevz Skerget, Barbara Skopec, Samo Zver
Journal: Blood (2016)
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Authors: L. Paz-Ares, C.J. Langer, S. Novello, B. Halmos, Y. Cheng, S.M. Gadgeel, R. Hui, S. Sugawara, H. Borghaei, R. Cristescu, D. Aurora-Garg, A. Albright, A. Loboda, J. Kobie, J. Lunceford, M. Ayers, G.M. Lubiniecki, M.C. Pietanza, B. Piperdi, M.C. Garassino
Journal: Annals of Oncology (2019)
Randomised phase II trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)
Authors: P.C. Petersen, L. Noergaard Petersen, I.R. Vogelius, J.K. Bjerregaard, L. Baeksgaard
Journal: Annals of Oncology (2019)
Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients
Authors: T. Pua, A. P. Novetsky, S. V. Blank
Journal: Journal of Clinical Oncology (2009)

5571 Background: The Child-Pugh score was designed to predict surgical outcome for patients with liver cirrhosis. This score is comprised of five variables (ascites, bilirubin, albumin, prothrombin time and encephalopathy) that were thought to determine prognosis. Epithelial ovarian cancer (EOC) and cirrhosis share manifestations of increased abdominal girth, ascites, malnutrition and abnormal laboratory findings. In this study, we evaluate the application of the Child-Pugh score to assess EOC outcome. Methods: A review of EOC patients (pts) undergoing primary cytoreductive surgery at our institution from 2003 to 2008 was performed. Pts without preoperative serum bilirubin, albumin, prothrombin time or documentation of ascitic volume were excluded. Women were divided into either Child class A (Child score &lt;6) or Child class B/C (&gt;6). Estimated blood loss, ICU admission, minor (infection, transfusion, ileus/bowel obstruction) and major complications (re-operation, peri-operative death, hospital stay &gt;14 days) and survival analysis were evaluated using chi square and Cox proportional hazards model, respectively. Results: A total of 105 patients were evaluated, 29 with early stage (I/II) and 76 with late stage (III/IV) disease. Estimated blood loss was not significantly different between Child class A vs B/C groups (469 ml vs 628 ml, p = 0.45). Optimal cytoreduction was achieved in 92.3% vs 65.8%, respectively (p = 0.001). Post-operative ICU admission (4.8% vs 23.7%, p = 0.004) and minor complication (35% vs 66%, p = 0.003) rates were also significantly lower in the Child A vs B/C group. Of note there were 4 peri-operative deaths, all in the B/C group (p = 0.01). Length of hospital stay between the two groups were 4 vs 8.4 days, respectively (p = 0.008). Women in Child class B/C had a hazard ratio of 12.4 (95% CI 1.5 - 100.7) for death as compared to those in Child class A. Conclusions: Application of the Child classification to women with ovarian cancer revealed increased rates of suboptimal cytoreduction and peri-operative complications including ICU admission, infection, transfusion and death. EOC patients with higher Child score prior to surgery may consider neoadjuvant chemotherapy to decrease morbidity of surgery. No significant financial relationships to disclose.
Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Authors: R. Galot, C. Van Marcke de Lummen, R. Helaers, A. Mendola, R.-M. Goebbels, X. Caignet, J. Ambroise, K. Wittouck, M. Vikkula, N. Limaye, J.-P. Machiels
Journal: Annals of Oncology (2019)
Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study
Authors: F. de Marinis, K.K. Laktionov, A. Poltoratskiy, I. Egorova, M. Hochmair, A. Passaro, M.R. Migliorino, G. Metro, M. Gottfried, D. Tsoi, G. Ostoros, S. Rizzato, G.Z. Mukhametshina, M. Schumacher, S. Novello, W. Tang, L. Clementi, A. Cseh, D.M. Kowalski
Journal: Annals of Oncology (2019)
A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
Authors: A.W. Tolcher, G. Falchook, J.C. Bendell, D. Ungar, J. Boni, G. Chao, M.R. Patel
Journal: Annals of Oncology (2019)
Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first-line chemotherapy
Authors: Z. Zafeiriou, A. Koutoulaki, F. Koinis, D. Aggouraki, N.K. Vardakis, E.K. Vetsika, K. Kotta, D. Mavroudis, V. Georgoulias, A. Kotsakis
Journal: Annals of Oncology (2019)
Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
Authors: K.L. Reckamp, W. Akerley, E. Calvo, J. Clarke, M.J. Edelman, K. He, V. Moreno, J.W. Neal, T.K. Owonikoko, J.D. Patel, S.P. Patel, J.W. Riess, A.G. Sacher, S. Turcotte, L.C. Villaruz, M.G. Zauderer, B. Farsaci, N. Skoura, M. Chisamore, M.L. Johnson
Journal: Annals of Oncology (2019)
The potential role of clusterin in chemoresponsiveness to gemcitabine in bladder cancer cells
Authors: Tony Luongo, Liana Adam, Wassim Kassouf, Gordon Brown, Colin P. Dinney
Journal: Cancer Research (2005)

791  Objectives: Clusterin expression is highly up regulated in several chemoresistant malignancies. The functional role of clusterin in the acquisition of a therapy - resistant phenotype in bladder cancer cell remains unknown. We hypothesize that clusterin plays an important role in cancer progression and emergence of chemotherapy resistant phenotype. We investigated the baseline clusterin expression of a variety of bladder cancer cell lines and correlate this expression with the chemosensitivity to gemcitabine in vitro. Methods: A bladder cancer cell panel, consisting of 253J, 253J B-V, 253J B-VR(resistant to taxotere), KU-7, UC-3, UC-5, UC-6, UC-10, and UC-13 were assessed for baseline clusterin expression via Western blot analysis. Chemosensitivity of KU-7 and 253J B-V to gemcitabine (1nM, 10nM, 100nM, and 1000nM) is determined via apoptosis and cell cycle analysis after 48 and 72hrs of treatment using propidium iodide and flow cytometry. We assessed changes in clusterin expression in vitro in KU-7 and 253J B-V bladder cancer cell lines following treatment with the same concentrations of gemcitabine (1nM-1000nM) via Western blot. Results: By screening a variety of human bladder cancer cell lines we observed a wide spectrum of clusterin levels. The steady state levels were high for KU-7, UC-3, and 253J B-VR and low for the rest. Cells with low clusterin expression levels, such as 253J B-V, showed sensitivity to gemcitabine with dose dependent apoptosis, reaching 40% apoptosis at 100nM at 72hrs. In addition, gemcitabine induced a dose dependent G0/G1 arrest with decreased S-phase after 48hrs. In contrast, KU-7, cell line with high clusterin expression, showed resistance to gemcitabine at all concentrations and no quantitative change in cell cycle. The chemoresponsiveness of 253J BV and KU-7 cell lines to gemcitabine correlated with changes in clusterin expression during gemcitabine treatment over 48 and 72hrs. 253J BV cell line showed a decrease in clusterin expression at 100 and 1000nM of gemcitabine at 48 and 72hrs on western blot. KU-7 cells showed a dose-dependent increase in clusterin expression, most pronounced at 72 hrs. Conclusions: We observed a differential expression of clusterin among several bladder cancer cell lines. We also observed high baseline clusterin expression, such as in KU-7, appeared to be associated with resistance to gemcitabine and induction of clusterin expression appeared to confer a chemoresistant phenotype. This data provides a rationale to examine clusterin’s role in modulating reponse to chemotherapy. Determine whether antisense (ASO) targeting the clusterin gene enhances apoptosis induced by gemcitabine and evaluate whether combined treatment with clusterin ASO plus gemcitabine enhances chemosensitivity in vitro and in orthotopic and subcutaneous bladder tumor models. This would enhance our understanding of clusterin’s role as a surivival factor in bladder cancer.
Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma
Authors: B. Fairfax, C.A. Taylor, R.A. Watson, I. Nassiri, H. Fang, E. Mahe, R. Cooper, S. Danielli, V.K. Woodcock, Z. Traill, J.C. Knight, M. Payne, M.R. Middleton
Journal: Annals of Oncology (2019)
NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation
Authors: Ming Xiong, Liang Chen, Lijie Zhou, Yong Ding, Gallina Kazobinka, Zhaohui Chen, Teng Hou
Journal: Theranostics (2019)

Purpose: Nudix Hydrolase 21 (NUDT21) is a crucial mediator involved in alternative polyadenylation (APA), and this molecule has been reported to be a tumor suppressor in human cancers.However, neither the role NUDT21 plays in bladder cancer (BC) nor the mechanisms which are involved have been investigated.Methods: Expression levels of NUDT21 in BC were evaluated with real-time PCR, western blotting, and immunohistochemistry (IHC).In vitro and in vivo assays were performed to investigate the function of NUDT21 in tumorigenesis in bladder cancer cells.The TOP/FOP flash reporter assay, western blot, and global APA site profiling analysis were used to identify the pathway which mediates the biologic roles of NUDT21 in BC.Results: NUDT21 expression is reduced in BC tissue and cells, and BC patients with lower NUDT21 expression have shorter overall and recurrent-free survival than patients with higher NUDT21 expression.NUDT21 ectopic expression or knockdown respectively profoundly inhibited or promoted the capacity of BC cells for proliferation, migration and invasion.We also identified a number of genes with shortened 3'UTRs through modulation of NUDT21 expression, and further characterized the NUDT21-regulated genes ANXA2 and LIMK2.We found NUDT21 modulates the expression of ANXA2 and LIMK2 in the Wnt/β-catenin and NF-κB signaling pathways.Conclusions: These findings show NUDT21 plays a crucial role in BC progression, at least in part through ANXA2 and LIMK2 which act by alternative polyadenylation.NUDT21 may thus have potential as a diagnostic and therapeutic target in treatment of BC.
Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals
Authors: Jana Blazkova, Eric W. Refsland, Katherine E. Clarridge, Victoria Shi, J. Shawn Justement, Erin D. Huiting, Kathleen R. Gittens, Xuejun Chen, Stephen D. Schmidt, Cuiping Liu, Nicole Doria-Rose, John R. Mascola, Alonso Heredia, Susan Moir, Tae-Wook Chun
Journal: Journal of Clinical Investigation (2019)

A number of highly potent and broadly neutralizing antibodies (bNAbs) against the human immunodeficiency virus (HIV) have recently been shown to prevent transmission of the virus, suppress viral replication, and delay plasma viral rebound following discontinuation of antiretroviral therapy in animal models and infected humans. However, the degree and extent to which such bNAbs interact with primary lymphocytes have not been fully delineated. Here, we show that certain glycan-dependent bNAbs, such as PGT121 and PGT151, bind to B, activated T, and natural killer (NK) cells of HIV-infected and -uninfected individuals. Binding of these bNAbs, particularly PGT121 and PGT151, to activated CD4+ and CD8+ T cells was mediated by complex-type glycans and was abrogated by enzymatic inhibition of N-linked glycosylation. In addition, a short-term incubation of PGT151 and primary NK cells led to degranulation and cellular death. Our data suggest that the propensity of certain bNAbs to bind uninfected/bystander cells has the potential for unexpected outcomes in passive-transfer studies and underscore the importance of antibody screening against primary lymphocytes.
The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Authors: N. Conlon, A. Browne, L. Breen, M. Lowry, L. O’Driscoll, M. Cremona, B.T. Hennessy, A.J. Eustace, N. O’Donovan, J. Crown, D.M. Collins
Journal: Annals of Oncology (2019)
Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome
Authors: Mario Annunziata, Roberto Latagliata, Alessandra Iurlo, Massimo Breccia, Isabella Capodanno, Claudia Baratè, Federica Sorà, Elena Crisà, Barbara Anaclerico, Alessandro Isidori, Nicola Sgherza, Antonella Gozzini, Sabina Russo, Paolo Avanzini, Caterina Musolino, Simona Sica, Michele Cedrone, Sara Galimberti, Dario Ferrero, Giuseppe Visani, Giuliana Alimena, Felicetto Ferrara, Antonella Russo Rossi
Journal: Blood (2016)
Preventing suicide in medical staff: let’s respect each other
Authors: Amanda Woods
Journal: BMJ (2019)

I was moved by Gerada’s reflections about her work with relatives bereaved by suicide of a doctor.1 One doctor dying by suicide every three weeks is shocking and tragic. This led me to consider how this figure compares with other groups. The highest rates of suicide are in manual workers, especially where there is a lack of job security and earnings …
Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
Authors: R. Tian, W. Guo, Y. Guo, X. Zhang, H. Zhu, F. Shen, J. Xu, X. Zhang, R. Wang, X. Ren, J. Li, X. Song
Journal: Annals of Oncology (2019)
Assessing the antitumor activity of MLN8237, an oral Aurora A small molecule inhibitor, in murine xenografts using FDG PET
Authors: Melissa Germanos, Rob Robertson, Donna Cvet, Jeffrey Ecsedy, Mark Manfredi, Matthew Silva
Journal: Cancer Research (2008)

3730  The Aurora family of mitotic kinases is instrumental for proper mitotic progression. Aurora A gene amplification has been detected in a variety of human cancers, leading to an interest in this target for new cancer medicines. Selective inhibition of Aurora A by MLN8237 has demonstrated potent anti-tumor activity in several preclinical models of human cancer grown in immunodeficient mice. In this study, we monitored the change in deoxy-2-[18F]fluoro-D-glucose (FDG) uptake in a murine xenograft model using positron emission tomography (PET). FDG-PET imaging provides a non-invasive method to monitor glucose uptake and metabolism of cells. In tumors, FDG-PET provides a means of evaluating disease burden and response to treatment. In this study, SCID mice bearing subcutaneous CWR22-RV1 (prostate cancer) tumors were treated p.o. with vehicle, MLN8237 at 10 mg/kg QD, or MLN8237 at 20 mg/kg BID (n=8 per group). On days 0 (prior to treatment), 4, 8, 11, 14, 16, and 23, microPET imaging was performed. Prior to scanning, animals were fasted for 6 hours to reduce the available glucose and enhance uptake of the FDG tracer. One hour prior to scanning, 300 μCi of FDG was injected via a tail vein and allowed to distribute for 60 minutes, and anesthetized animals were imaged. After attenuation correction, 3D images were reconstructed using ordered subset expectation maximization (OSEM), and a volume of interest (VOI) encompassing the entire tumor was drawn by hand. Analysis of the average standard uptake value (SUV) was performed. Tumor volume was also measured, and at the end of the study (day 23) the volumes of the 10 mg/kg QD and the 20 mg/kg BID groups were 37% and 91% lower than the vehicle-treated group, respectively. From the PET data, on day 8, the SUV of both the 10 mg/kg QD and 20 mg/kg BID groups were reduced by 27% (p